Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Pulmonology Reports
Published in: Current Pulmonology Reports 4/2015

01-12-2015 | Bronchiectasis (G Tino, Section Editor)

Inhaled antibiotics for bronchiectasis: are we there yet?

Authors: Chris Johnson, Charles S. Haworth

Published in: Current Pulmonology Reports | Issue 4/2015

Login to get access

Abstract

Chronic infection in non-CF bronchiectasis is an important risk factor for disease progression, poor quality life, admission to hospital and perhaps reduced life expectancy. The use of long-term oral and inhaled antibiotics has been included in expert consensus-based guidelines but until recently supporting evidence has been weak. The design, duration and size of adequately powered clinical trials remain challenging, and this has been reflected in some of the reported outcomes. In addition, the tolerability of nebulised antibiotics remains an issue. Despite this, it is now possible to include inhaled antibiotics in treatment strategies and be more specific about antibiotic choice and dose. New inhaled antibiotic options continue to be developed. The most difficult challenge to the success of this intensive treatment will be the promotion of patient adherence.
Literature
1.
Ringshausen FC et al. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. PLoS One. 2013;8(8):e71109.PubMedCentralCrossRefPubMed
2.
3.
Chalmers JD et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–85.PubMedCentralCrossRefPubMed
4.
Pasteur MC et al. British thoracic society guidelines for non-CF bronchiectasis. Thorax. 2010;65(S1):i1–i58.CrossRefPubMed
5.
Vendrell M et al. Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery. Arch Bronchopneumol. 2008;44:629–40.CrossRef
6.
Cole PJ. Inflammation: a two-edge sword—the model of bronchiectasis. Eur J Respir Dis. 1986;69:6–15.
7.
Purcell P et al. Polymicrobial airway bacterial communities in adult bronchiectasis patients. BMC Microbiol. 2014;14(130):1–11.
8.
Rogers GB et al. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med. 2014;2(12):988–96.CrossRefPubMed
9.
Tunney MM et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med. 2013;187(10):1118–26.PubMedCentralCrossRefPubMed
10.
Chalmers JD et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186(7):657–65.CrossRefPubMed
11.
Martinez-Garcia MA et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132(5):1565–72.CrossRefPubMed
12.
Martinez-Garcia MA et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J. 2014;43(5):1357–67.CrossRefPubMed
13.
Stockley RA et al. Nebulised amoxicillin in chronic purulent bronchiectasis. Clin Ther. 1985;7:593–9.PubMed
14.
Hill SL et al. Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high dose orally or by inhalation. Thorax. 1986;41:559–65.PubMedCentralCrossRefPubMed
15.
Hill SL et al. The response of patients with purulent bronchiectasis to antibiotics for four months. Q J Med. 1988;66:163–73.PubMed
16.
Ramsey B et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340:23–30.CrossRefPubMed
17.•
Barker AF et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000;162:481–5. This prospective study of nebulised tobramycin demonstrated a significant improvement in bacterial load and an improvement in medical condition. However there was a high rate of adverse events associated with the active drug.CrossRefPubMed
18.
Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest. 2005;127:1420–6.CrossRefPubMed
19.•
Murray MP et al. A randomised controlled trial of nebulised gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011;183:491–9. This single blinded study of long term nebulised gentamicin versus normal saline demonstrated a good microbiological response, improved exercise tolerance, better quality of life and an increased time to first exacerbation.CrossRefPubMed
20.
Serisier DJ, Bowler SD. Randomised controlled trial of nebulised gentamicin in non-cystic fibrosis bronchiectasis…without patient blinding. Am J Respir Crit Care Med. 2012;186(5):461–2. author reply.CrossRefPubMed
21.
Steinfort DP, Steinfort C. Effect of long term nebulised colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J. 2007;37:495–8.CrossRefPubMed
22.
Dhar R et al. Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax. 2010;65:553.CrossRefPubMed
23.•
Haworth CS et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189(8):975–82. The first large randomised controlled trial of nebulised colistin in non-CF bronchiectasis. The protocol included the real world scenario of targeted treatment prior to the introduction of nebulised antibiotics. The results were supportive of a positive effect on bacterial load, symptom scores and in those with >80% adherence a clinical meaningful and significant increase in the time to first exacerbation.PubMedCentralCrossRefPubMed
24.
25.
26.
Oermann CM et al. An 18 month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol. 2010;45:1121–34.CrossRefPubMed
27.•
Barker AF et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet. 2014;2(9):738–49. Two large randomised controlled trials of nebulised AZLI in non-CF bronchiectasis. There was a high adverse event rate and the studies did not demonstrate a positive clinical benefit. However there are a number of factors relating to study design that are likely to have influenced this outcome.PubMed
28.
Wilson R et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 2013;41(5):1107–15.PubMedCentralCrossRefPubMed
29.
Serisier DJ et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo controlled trial. Thorax. 2013;68:812–7.CrossRefPubMed
Metadata
Title
Inhaled antibiotics for bronchiectasis: are we there yet?
Authors
Chris Johnson
Charles S. Haworth
Publication date
01-12-2015
Publisher
Springer US
Published in
Current Pulmonology Reports / Issue 4/2015
Electronic ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-015-0126-4

Other articles of this Issue 4/2015

Current Pulmonology Reports 4/2015 Go to the issue

Smoking Cessation (S Veeraraghavan, Section Editor)

Computed tomography of smoking-related lung disease: review and update

Smoking Cessation (S. Veeraraghavan, Section Editor)

Pharmacological therapies in smoking cessation: an evidence-based update

Smoking Cessation (S. Veeraraghavan, Section Editor)

Waterpipe tobacco-smoking: a new smoking epidemic among the young?

Bronchiectasis (G Tino, Section Editor)

Diagnostic approach to bronchiectasis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits